{"id":4647,"count":22,"description":"Categoria MedsBase pentru tratamentul anxiet\u0103\u021bii situa\u021bionale este un termen impropriu care merit\u0103 \u00een\u021beles.<\/strong> Fiecare produs de pe aceast\u0103 pagin\u0103 este un medicament psihiatric pentru uz cronic \u2014 antidepresive (SSRI, SNRI, TCA), antipsihotice atipice sau agen\u021bi \u00eenrudi\u021bi prescri\u0219i \u0219i titra\u021bi pe parcursul s\u0103pt\u0103m\u00e2nilor pentru tulbur\u0103ri de dispozi\u021bie, anxietate \u0219i psihoze diagnosticate. Niciunul dintre aceste medicamente nu este de prim\u0103 inten\u021bie pentru anxietatea acut\u0103, legat\u0103 de performan\u021b\u0103 (\u201csitua\u021bional\u0103\u201d)<\/strong> (flying, public speaking, exams, interviews) — for those situations, the clinically appropriate options are short-acting beta-blockers (propranolol), benzodiazepines, and sedating antihistamines (hydroxyzine), none of which are stocked in this category. If your need is occasional acute anxiety only, the medications below are not the right starting point. If your need is a diagnosed depressive, anxiety, bipolar, or psychotic disorder requiring long-term treatment, the index below organises what is here by drug class.\n\nSSRIs — selective serotonin reuptake inhibitors\nFirst-line antidepressants worldwide for major depressive disorder (MDD), generalised anxiety disorder (GAD), panic disorder, social anxiety disorder, OCD, PTSD, and PMDD. Onset 4–6 weeks for full mood response; anxiety symptoms often respond at 1–2 weeks. Common side effects are nausea, GI upset (usually transient), sexual dysfunction, and modest weight changes. Discontinuation must be tapered — never stopped abruptly.\n\nSertralin\u0103<\/strong> \u2014 cel mai curat profil CYP dintre SSRI \u0219i preferat \u00een sarcin\u0103\/al\u0103ptare: Sertafine<\/a>, Sertagress<\/a>, Sertima<\/a>, Zosert<\/a> (50\/100 mg). Aprobat pentru TDM, TOC (adul\u021bi \u0219i copii), panic\u0103, anxietate social\u0103, TSPT, TDPM.\nParoxetin\u0103<\/strong> \u2014 Xepar<\/a> 20 mg. The SSRI with the broadest range of FDA-approved anxiety indications (MDD, GAD, social anxiety, panic, OCD, PTSD, PMDD). Trade-offs: worst discontinuation syndrome of the class (very short half-life), highest weight gain, highest sexual dysfunction, pregnancy category D.\n\n\nSNRIs — serotonin-norepinephrine reuptake inhibitors\nSecond main first-line antidepressant class. Venlafaxine<\/strong> (eliberare prelungit\u0103) este aprobat\u0103 pentru tulburare depresiv\u0103 major\u0103 (MDD), tulburare de anxietate generalizat\u0103 (GAD), anxietate social\u0103 \u0219i tulburare de panic\u0103. Mecanismul variaz\u0103 \u00een func\u021bie de doz\u0103: efect asem\u0103n\u0103tor SSRI sub 150 mg\/zi, efect SNRI adev\u0103rat (cu inhibarea recapt\u0103rii norepinefrinei) la 150\u2013225 mg\/zi, cu efect maxim \u00een depresia rezistent\u0103 la tratament la 225\u2013375 mg\/zi \u00een MDD. Preocup\u0103ri specifice: cre\u0219terea tensiunii arteriale dependent\u0103 de doz\u0103 (monitorizarea TA la > 225 mg\/zi) \u0219i sindrom de suspendare sever (este necesar\u0103 reducerea treptat\u0103 a dozei). Mai periculos \u00een caz de supradoz\u0103 dec\u00e2t SSRI-urile.\n\nAffexor XR<\/a> \u00b7 Venish SR<\/a> \u00b7 Venpad XR<\/a> \u00b7 Ventab XL<\/a> — all venlafaxine extended-release in 37.5 \/ 75 \/ 150 mg strengths.\n\n\nTricyclic antidepressants (TCAs) and TCA-related anxiolytics\nOlder antidepressant class largely replaced by SSRIs\/SNRIs for first-line depression, but still useful for refractory depression, neuropathic pain, panic disorder, paediatric enuresis, and migraine prevention. Anticholinergic burden, sedation, orthostatic hypotension, and cardiac toxicity in overdose are the main concerns — baseline ECG before starting in patients over 50.\n\nD-mine<\/a> \u2014 imipramin\u0103 25 mg, primul antidepresiv triciclic; pentru MDD, tulburare de panic\u0103, enurez\u0103 pediatric\u0103, durere neuropatic\u0103.\nPrimox<\/a> \u2014 nortriptilin\u0103 25 mg, ATC cu amin\u0103 secundar\u0103 cu cea mai mic\u0103 sarcin\u0103 anticolinergic\u0103 din clas\u0103; triciclic de prim\u0103 inten\u021bie pentru prevenirea migrenei \u0219i durerea neuropatic\u0103 cronic\u0103.\nOpiprol<\/a> \u2014 opipramol 50 mg, un anxiolitic atipic \u00eenrudit cu ATC care nu prime\u0219te,<\/em> inhibit serotonin reuptake (its mechanism is sigma-receptor agonism plus antihistamine); primary use is generalised anxiety disorder and somatoform disorders, mostly in German-speaking Europe.\n\n\nAtypical antidepressants — mirtazapine, trazodone, vilazodone\nThree drugs with mechanisms outside the SSRI \/ SNRI \/ TCA paradigm.\n\nNasdep<\/a> \u2014 mirtazapina 30 mg, un NaSSA tetraciclic cu puternic\u0103 activitate antihistaminic\u0103 H1. Model paradoxal de sedare (mai sedativ la 15 mg dec\u00e2t la 45 mg). Cre\u0219tere semnificativ\u0103 \u00een greutate. Cel mai potrivit pentru TCM cu insomnie, apetit sc\u0103zut sau pierdere \u00een greutate, unde efectele secundare lucreaz\u0103 pentru pacient \u0219i nu \u00eempotriva lui.\nTrazalon<\/a>, Trazonil<\/a>, Tridon<\/a> \u2014 trazodon\u0103 (50 \/ 100 mg). Indicat pentru TCM, dar utilizarea dominant\u0103 modern\u0103 este off-label la doze mici (25\u2013100 mg) pentru insomnie cronic\u0103. F\u0103r\u0103 poten\u021bial de dependen\u021b\u0103; principalele preocup\u0103ri sunt hipotensiunea ortostatic\u0103 (blocare alfa-1), priapism la b\u0103rba\u021bi (rar 1 la 1.000\u201310.000 \u2014 urgen\u021b\u0103 dac\u0103 dureaz\u0103 > 4 ore) \u0219i prelungirea QT la doze mai mari.\nVilano<\/a> \u2014 vilazodon\u0103 40 mg, un SSRI plus agonist par\u021bial 5-HT1A cu efecte secundare sexuale mai reduse dec\u00e2t alte SSRI. Trebuie luat cu o mas\u0103 de \u2265 500 de calorii<\/strong> — bioavailability halves on an empty stomach.\n\n\nAtypical antipsychotics\nSecond-generation antipsychotics for schizophrenia, bipolar disorder, and adjunctive treatment of treatment-resistant depression. All carry an FDA black-box warning for increased mortality in elderly with dementia-related psychosis. Monitor weight, fasting glucose, and lipids at baseline, 3 months, then annually (metabolic syndrome is a class risk).\n\nPsyquit<\/a> \u00b7 Q-Siz SR 400<\/a> \u2014 quetiapina \u00een formul\u0103ri cu eliberare imediat\u0103 \u0219i prelungit\u0103. Sedare puternic\u0103; indica\u021bii largi (schizofrenie, manie bipolar\u0103 \u0219i depresie, adjunct TCM).\nRiscon<\/a> \u2014 risperidon\u0103 pentru schizofrenie, manie bipolar\u0103 \u0219i iritabilitate \u00een autism. Efect secundar distinctiv: cea mai mare hiperprolactinemie dintre atipice (galactoree, ginecomastie, amenoree, disfunc\u021bie sexual\u0103). Trecerea \u00een EPS asem\u0103n\u0103toare antipsihoticelor tipice la doze > 6 mg\/zi.\nZipsydon<\/a> \u2014 ziprasidon\u0103 pentru schizofrenie \u0219i manie bipolar\u0103. Cel mai mic risc metabolic dintre atipicele comune (mai pu\u021bin\u0103 cre\u0219tere \u00een greutate, impact mai mic asupra glicemiei \/ lipidelor), dar cea mai mare prelungire QT (ECG de baz\u0103 obligatoriu). Trebuie luat cu o mas\u0103 de \u2265 500 de calorii<\/strong>.\n\n\nFirst-generation antipsychotic + anticholinergic combination\nTrinicalm Plus<\/a> — trifluoperazine 5 mg + trihexyphenidyl 2 mg. A high-potency typical antipsychotic paired with an anticholinergic anti-Parkinson agent to pre-empt the EPS (parkinsonism, dystonia, akathisia) that high-potency typical antipsychotics routinely cause. Used where typical antipsychotics remain first-line by cost or availability and in stable legacy regimens. Modern practice generally favours atypical antipsychotic monotherapy where available — lower EPS risk, lower tardive dyskinesia risk, and no routine anticholinergic cover required. Trihexyphenidyl has recognised abuse potential at supratherapeutic doses.\n\nHow to choose\nFor untreated MDD or anxiety disorders without prior treatment, sertralina<\/strong> este cea mai justificat\u0103 alegere de prim\u0103 inten\u021bie datorit\u0103 profilului curat de interac\u021biuni medicamentoase, indica\u021biilor largi \u0219i siguran\u021bei \u00een sarcin\u0103\/al\u0103ptare. Pentru TCM cu insomnie prominent\u0103, sc\u0103dere a apetitului sau pierdere \u00een greutate, mirtazapina<\/strong> is a sensible alternative because the side effects work in the patient's favour. For chronic insomnia not responding to behavioural interventions, low-dose trazodon<\/strong> r\u0103m\u00e2ne cel mai prescris hipnotic off-label la nivel global. Pentru schizofrenie sau tulburare bipolar\u0103 tip I, un antipsihotic atipic (quetiapina, risperidon\u0103, ziprasidon\u0103) este de prim\u0103 inten\u021bie \u00een locul antipsihoticelor tipice \u00een practica modern\u0103. Niciunul dintre aceste medicamente nu \u00eenlocuie\u0219te evaluarea psihiatric\u0103 individualizat\u0103<\/strong> \u2014 alegerea corect\u0103 depinde de diagnostic, comorbidit\u0103\u021bi, istoricul tratamentelor anterioare, interac\u021biunile medicamentoase \u0219i statutul de sarcin\u0103.\n\nStoc de la produc\u0103tor certificat WHO-GMP \u00b7 ambalaj discret \u00b7 livrare worldwide \u00b7 peste 1.400 de clien\u021bi \u00een peste 50 de \u021b\u0103ri.<\/strong> Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de Politica noastr\u0103 de Reexpediere Garantat\u0103<\/a>.","link":"https:\/\/medsbase.com\/ro\/situational-anxiety-treatment\/","name":"Tratament pentru anxietate situa\u021bional\u0103","slug":"situational-anxiety-treatment","taxonomy":"product_cat","parent":3223,"meta":[],"menu_order":0,"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat\/4647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/taxonomies\/product_cat"}],"up":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat\/3223"}],"wp:post_type":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product?product_cat=4647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}